Menu Search
Equities

Starpharma Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PQ6:BRN

Starpharma Holdings Ltd

Actions
  • Price (CHF)0.082
  • Today's Change0.00 / 0.00%
  • Shares traded12.00k
  • 1 Year change--
  • Beta0.1340
Data delayed at least 15 minutes, as of Feb 14 2024.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Starpharma Holdings Limited is an Australia-based biotechnology company specializing in advancing dendrimer technology. The Company's principal activities are focused on the research, development and commercialization of dendrimer technology for pharmaceutical and healthcare applications. The Company's portfolio of dendrimer-based products includes three clinical-stage dendrimer enhanced product (DEP) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over the counter (OTC) products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, the Company has a preclinical pipeline of DEP radiopharmaceuticals in development. It also manufactures and sells SPL7013 (astodrimer sodium) proprietary products: VivaGel BV, Viraleze nasal spray, and VivaGel condom. The Company has applied its DEP technology to the innovative area of antibody-drug conjugates.

  • Revenue in AUD (TTM)5.85m
  • Net income in AUD-9.99m
  • Incorporated1997
  • Employees50.00
  • Location
    Starpharma Holdings Ltd4-6 Southampton Crescent, AbbotsfordMELBOURNE 3067AustraliaAUS
  • Phone+61 38532-2700
  • Fax+61 39510-5955
  • Websitehttps://www.starpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.